Navigation Links
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Date:5/30/2008

Gene Expression Profiling of Tumor is Correlated With Clinical Response

CHICAGO, May 30 /PRNewswire-FirstCall/ -- New data presented by GlaxoSmithKline (GSK) today highlighted the potential of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) through results of three studies evaluating highly targeted immunotherapy as a treatment for metastatic melanoma and non-small cell lung cancer (NSCLC). These data were presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract Nos: 9065(1), 9045(2) and 7501(3)).

A randomized, open label Phase II study designed to evaluate two different formulations of the MAGE-A3 ASCI in patients with metastatic melanoma has been conducted. In this study, the ASCI, which is a combination of MAGE-A3 recombinant protein and a GSK proprietary Adjuvant System, was evaluated and resultant data suggest a positive trend for clinical response. These data also demonstrate the induction of a desirable immune response, including humoral and cellular responses. These study results represent a second positive trend for clinical activity for the novel MAGE-A3 cancer immunotherapeutic, following encouraging clinical results reported in a separate double-blind, placebo-controlled Phase II study of patients with NSCLC(4). The encouraging results from the Phase II NSCLC study have led to a Phase III safety and efficacy trial in MAGE-A3-positive NSCLC patients (stage IB, II and IIIA) who have undergone complete surgical resection (MAGRIT; MAGE-A3 Adjuvant Non-Small Cell LunG CanceR ImmunoTherapy).

At this year's ASCO, GSK also presented data regarding the use of the genetic profiling of melanoma in predicting clinical outcomes of treatment with MAGE-A3 ASCI. Biopsies performed on the melanoma tumors prior to immunization were used to identify genetic markers expressed by the disease. These markers enabled researchers to establish a correlation between the expression
'/>"/>

SOURCE GlaxoSmithKline (GSK)
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Presentation of Data on Progens Cancer Epigenetic Targets Platform
2. Genmab Announces Updates on Phase III Cancer Studies
3. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
6. Prostate Cancer Treatment Offers Results Without Side Effects
7. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
8. First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
9. Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
10. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
11. Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...BRUNSWICK,N.J.,Nov.25/PRNewswire/--SwissrayInterna...ography( ddR )systems,announcedtodaythatitsoperati...gtermviewtowardsgrowingSwissray,smedicalimagingbra...roperty,aswellascontractsandinventory.After25years...xtleveloftechnologicaladvancementswithstableandste...
(Date:11/25/2009)...IEGO,Nov.25/PRNewswire-FirstCall/--NuVasive,Inc.(N...pingproductsforminimallydisruptivesurgicaltreatmen...ncecallonMonday,November30,2009,at5:30p.m.ET/2:30p...ativetoreimbursementfortheCompany,sproductsandwill...ionandanswersession.Thedial-innumbersare1-877-407-...
(Date:11/25/2009)...ORK,Nov.25/PRNewswire/--Reportlinker.comannouncest...ue: ,, PainManagement-GlobalTrends ,, h...t---Global-Trends.html ,, Widespreadavailabili...andtheadventofnewdrugshaveacceleratedthepaceofgrow...imbursementstructurecontinuetoshapedemandforservic...
Breaking Medicine Technology:Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Newly Updated Pharmacy State Law Compendium Available 5335 1Newly Updated Pharmacy State Law Compendium Available 5335 2Major health care challenges persist for D C children despite high rates of health insurance coverage RAND study finds 59154 1Major health care challenges persist for D C children despite high rates of health insurance coverage RAND study finds 59154 2Major health care challenges persist for D C children despite high rates of health insurance coverage RAND study finds 59154 3CSI in a virtual world 3A New grant furthers NC States work in forensic science 10303 1CSI in a virtual world 3A New grant furthers NC States work in forensic science 10303 2CSI in a virtual world 3A New grant furthers NC States work in forensic science 10303 3
... - Cytogen,Corporation (NASDAQ: CYTO) today announ...shed at upcoming major medical meetings. The,data ...QUADRAMET(R),(samarium Sm-153 lexidronam injection...astatic bone disease arising from prostate,cancer ...,evaluating the outcomes of prostate cancer patien...
...-- Once-daily,dosing with Otsuka,s investigational... antagonist, was associated with improvements,in s...ailure (ADHF),in hospitalized patients receiving c...ir long-term survival versus placebo.(1) These,dat...e,international landmark trial Efficacy of Vasopre...
Other Medicine Technology:New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 2New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 3New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 4New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
(Date:11/26/2009)... Fans get a bigger thrill when on an emotional rol...v. 26 (HealthDay News) -- Call it the fear factor ...ggests that spectators -- especially those who roo...faction if it,s a closely contested match and vict...even despair. , Chew on that this Thanksgiving ...
(Date:11/26/2009)..., Research Triangle Denta...entral North Carolina, today announced the expansi...fied LUMINEER Dentist, Dr. Doug Macmillan. , ...rch Triangle Dental is pleased to announce that Dr...st, recently completed an additional advanced trai...
(Date:11/25/2009)...,, EDINA,Minn.,Nov.25/PRNewswire-USNewswire/...dentist.Butachiropractorcanalsogivepatientsthehelp...hichiswhereyourjaw(mandible)contacts/connectswithy...sassociatedwithTMJdysfunctionarepainwithchewing,cl...ausedfromTMJdysfunctionincluding:headaches,fatigue...
(Date:11/25/2009)...,, TORONTOandCALGARY,Nov.25/PRNewswire/-Sent...sonanceImaging(MRI)coilsandsoftwareandCalgaryScien...logies,haveintroducedawebversionofAegis(TM)Breast4...veinterfaceisthefirsttrulyzero-footprintWebclientb...tific,sPureWeb(TM)platformallowsforzero-footprinta...
(Date:11/25/2009)...,, SILVERSPRING,Md.,Nov.25/PRNewswire-USNews...FDA,sCenterforDrugEvaluationandResearch,titled"ADi...,"appearsintheNov.26,2009issueofTheNewEnglandJourn...cgi-bin/prnh/20090824/FDALOGO ) ,, Inthearticle...naccesstopainmedicationforthosewhoneeditandmanagin...
Breaking Medicine News(10 mins):Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
...search Network is very near to achieving one of to...ge in the best possible health conditions.// ...nish universities of Seville, Oviedo, Saragossa, B...beings and present in many types of food – delays ...
...ev has launched a seven-day camp in this Taj Mahal...on sex and other licentious activities.// Ram...d, said he was opposed to sex education being give...vised the young to 'exercise restraint' rather tha...
... polluted river and a handful of concerned citizen...heralded World Earth Day Sunday, //by raising its ...ile ecosystem. 'We are on the brink of a cha... needs to be addressed immediately and a day such ...
...a massive immunization drive aimed at protecting m...eak. According to health experts, nearly 10% of th... Iraq's Ministry of Health is conducting the...ld Health Organization and UNICEF have got togethe...
... the US has sentenced a man to prison for conceali...to a plasma collection center at Hammond.// ...o selling blood contaminated with the HIV in Septe...a is the largest single component of blood, making...
...as combined nanotechnology and biology to enable t...rly results. Dr. Samuel is the director of the Ins...western University. He suggests that nanotechnolog...logy might achieve in regenerative medicine, paral...
Other Medicine News:Health News:High Melatonin can Help Delay Ageing 2Health News:Earth Day Celebrated With Hopes of a Greener Tomorrow 2Health News:Nanotechnology Could Treat Spinal Cord Injuries, Diabetes, and Parkinson's Disease 2
... Touch control panel with 3 charging wells. Availa...Blue and Cinnamon. Spring balanced refractor and s...ction for lifelong quality. Sealed hydraulic syste...ement. Chair back reclines manually to fully horiz...
...eveloped the patented HydroKeratome corneal cuttin...t and industry experts believe it will replace the...okeratome, currently used in the LASIK refractive ...Company has demonstrated that its proprietary tech...
2.5v Ophthalmoscope Set
3.5v Coaxial Ophthalmoscope Set
Medicine Products: